反应详情

A solution of 4-(4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)aniline (47 mg, 0.097 mmol) in dichloromethane (3 mL) was treated with triethylamine (0.13 mL), followed by triphosgene (14 mg, 0.048 mmol). After the passage of five minutes, cyclopropylamine (0.14 mL) was added. The mixture was concentrated to dryness under reduced pressure. The resultant residue was purified via reverse-phase high performance liquid chromatography using a Phenomenex Gemini 21 mm×100 mm column, running a gradient elution of 10% acetonitrile/90% of 0.1% aqueous trifluoroacetic acid to 75% acetonitrile over 30 minutes. After the concentration of fractions under reduced pressure, 1-cyclopropyl-3-(4-{4-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)-1-[1-(2,2,2-trifluoroethyl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-6-yl}phenyl)urea (67 mg) was obtained. MS (ES+): 571.5, 572.5 (M+H)+

1. concentrationThe mixture was concentrated to dryness under reduced pressure
2. customThe resultant residue was purified via reverse-phase high performance liquid chromatography
3. washa gradient elution of 10% acetonitrile/90% of 0.1% aqueous trifluoroacetic acid to 75% acetonitrile over 30 minutes